Health Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been assigned an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $9.27.

A number of analysts have recently issued reports on HCAT shares. Stifel Nicolaus lowered their price target on Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a research note on Thursday, February 27th. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a research note on Wednesday, January 8th. Canaccord Genuity Group dropped their target price on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 21st. Royal Bank of Canada decreased their price target on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 27th. Finally, Wells Fargo & Company lowered their price target on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 21st.

Health Catalyst Trading Down 1.1 %

HCAT stock opened at $4.55 on Friday. Health Catalyst has a 12-month low of $3.76 and a 12-month high of $9.24. The business’s 50-day moving average is $5.03 and its 200 day moving average is $6.86. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock has a market cap of $319.46 million, a price-to-earnings ratio of -3.37 and a beta of 1.41.

Insider Activity at Health Catalyst

In related news, Director Duncan Gallagher sold 4,500 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $6.93, for a total value of $31,185.00. Following the transaction, the director now directly owns 69,938 shares in the company, valued at approximately $484,670.34. This represents a 6.05 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Linda Llewelyn sold 6,442 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $5.80, for a total value of $37,363.60. Following the sale, the insider now directly owns 92,260 shares of the company’s stock, valued at approximately $535,108. This trade represents a 6.53 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 61,030 shares of company stock valued at $330,757. 2.50% of the stock is owned by company insiders.

Institutional Trading of Health Catalyst

Several institutional investors and hedge funds have recently bought and sold shares of HCAT. Group One Trading LLC boosted its stake in Health Catalyst by 107.6% during the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock worth $31,000 after buying an additional 2,260 shares during the period. Two Sigma Securities LLC lifted its holdings in shares of Health Catalyst by 19.5% in the 4th quarter. Two Sigma Securities LLC now owns 17,510 shares of the company’s stock worth $124,000 after acquiring an additional 2,862 shares during the last quarter. Legato Capital Management LLC boosted its position in shares of Health Catalyst by 3.7% during the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock worth $622,000 after purchasing an additional 3,171 shares during the period. Quantbot Technologies LP purchased a new position in shares of Health Catalyst during the 4th quarter worth approximately $29,000. Finally, Quest Partners LLC acquired a new stake in Health Catalyst in the 3rd quarter valued at approximately $34,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.